Plasma EGFR and Her2 levels in non-small cell lung cancer patients treated with gefitinib

• DOI: 10.1200/jco.2008.26.15_suppl.19007
• Publication Date: 2017-02-24T07:33:44Z
• Authors: K. Kasahara; S. Tamori; A. Sakai; Y. Tambo; T. Araya; T. Sone; H. Kimura; M. Fujimura
• Keywords: Log-rank test

19007 Background: Although EGFR mutation is a strong predictive factor of EGFR-TKI, it difficult to obtain tumor tissue which suitable examine mutations in patients (pts) with metastatic non-small cell lung cancer (NSCLC). The objectives study are evaluate roles plasma and HER2 levels as biomarker gefitinib treatment. Methods: Patients: pts who histologically or cytologically proven NSCLC received 250 mg daily. Plasma were measured by ELISA kit (Oncogene Science, USA) manufacture’s instruction. Tumor responses evaluated RECIST guidelines. Time progression (TTP) overall survival (OS) calculated the Kaplan-Meier method. Groups compared using log-rank test. Risk factors associated Cox proportional hazards regression modeling multivariable analysis. Results: Of 93 enrolled this investigation, 37 (40%) female 34 (37%) had never smoked. most common histological subtype was adenocarcinoma (79%) 66 (70%) good PS 0–1. 22 (24%) achieved PR 32 (33%) SD their response. Pretreatment 40.0 8.8 ng/ml, respectively. There no significant correlation between patients’ characteristics. significantly higher than that PD (42.81 ng/ml vs 36.02 p=0.049). High group (EGFR >40 ng/ml) longer OS (11.1 months high vs. 4.8 low group), TTP (3.3 1.4 group) <40 ng/ml). better subgroup such male (9.0 3.2 non-adenocarcinoma (6.4 2.7 negative (7.6 4.6 group). On analysis, remained improved OS. did not associate gefitinib, TTP, Conclusions: may be predictor clinical benefit gefitinib. No financial relationships disclose.